Insufficient autophagy promotes bronchial epithelial cell senescence in chronic obstructive pulmonary disease
Of note, all the studies undertaken in the OCC included in this meta-analysis used 3 T MRS strength, whereas there was variation in MRS strength across the other brain regions (7 T was used for two MFC studies, with 3 T used for three MFC studies)
If the application is accepted and approved, the medication could become available as early as late 2027, although the timeline will ultimately depend on the FDA review process
Who Should Consider GLP-1: A Provider-Guided Framework GLP-1 therapy may be medically appropriate for individuals with BMI 30, OR BMI 2729.9 with weight-related comorbidities (hypertension, type 2 diabetes, coronary heart disease), OR lower BMI with evidence of metabolic dysfunction (prediabetes, insulin resistance, dyslipidemia)
Experimental models have shown that DSIP administration increases GABAergic activity while reducing excitatory neurotransmission in cortical and limbic regions
Pitfalls in the quantitative imaging of glutathione in living cells